Some of FDA-Approved Cancer Drugs Containing Aminopyrimidine Structure

Yıl 2024, Cilt: 2 Sayı: 2, 88 - 97, 29.11.2024

İbrahim Evren Kıbrız , Muhammet Er , Mehmet Yakan , İrem Sena Görgeç , Beril Ece Yaşa

https://doi.org/10.70500/bjs.1580533

Öz

Cancer is a multifaceted disease marked by the uncontrolled growth and proliferation of tumors, which can harm healthy tissues and cause a range of health problems. Factors including genetics, environmental impacts, and lifestyle choices contribute to cancer development, creating a distinct risk profile for each person. Early detection and treatment methods are critical in the battle against cancer and can greatly influence the disease's progression. This study will offer insights into research on the effects of FDA-approved medications that contain the Amino Pyrimidine ring.

Anahtar Kelimeler

Cancer, Breast Cancer, Leukemia Cancer, Lung Cancer

Kaynakça

• NIH, “What-is-Cancer” https://www.cancer.gov/about-cancer/understanding/what-is-cancer. [Access Date: 24 October 2024].
• NIH, “Statistics” https://www.cancer.gov/about-cancer/understanding/statistics. [Access Date: 24 October 2024].
• NIH, “Treatment” https://www.cancer.gov/about-cancer/treatment. [Access Date: 24 October 2024].
• FDA, “FDA-Approved Drugs” https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. [Access Date: 24 October 2024].
• S., Li, J., Chen, C., Feng, W. F., Yang and M., Ji, “A new route for the synthesis of Palbociclib,” Chem. Pap. vol. 73, pp. 3043–3051, 2019, doi: 10.1007/s11696-019-00841-7.
• Pharmacyl, “Antimetabolites“ https://www.pharmacy180.com/article/antimetabolites-2436/. [Access Date: 24 October 2024].
• Google Patents, “Ribociclib” https://patents.google.com/patent/WO2016192522A1/en. [Access Date: 24 October 2024].
• G., Erickson, J., Guo, M., McClure, M., Mitchel, M. C. Salaun and A., Whitehead, “Synthesis of Lapatinib via direct regioselective arylation of furfural,” Tet. Lett. vol. 55, no. 43, pp. 60076010, 2014, doi: 10.1016/j.tetlet.2014.09.039.
• Google Patents, “Ibrutinib” https://patents.google.com/patent/WO2017134588A1/en. [Date of Access: 24 October 2024].
• S., Wang, X. H., Yuan, S. Q., Wang, W., Zhao, X. B. Chen, and B., Yu, “FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application,” Eur. J. Med. Chem., vol. 214, pp. 113218, 2021, doi: 10.1016/j.ejmech.2021.113218.
• N., Sun, C., Ren, and Y., Kong, “Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance,” Eur. J. Med. Chem., vol. 193, pp. 112190, 2020, doi: 10.1016/j.ejmech.2020.112190.
• ACS, “Bleomycin” https://www.acs.org/molecule-of-the-week/archive/b/bleomycin.html. [Access Date: 24 October 2024].
• A., Kompella, B. R. K., Adibhatla, P. R. Muddasani, S., Rachakonda, V. K., Gampa and P. K., Dubey, “A Facile Total Synthesis for Large-Scale Production of Imatinib Base,” Org. Process Res. Dev. vol. 16, no. 11, pp. 1794–1804, 2012, doi: 10.1021/op300212u.
• W., Nana, M., Haibo, D., Gagan, Z., Wei, H., Jianlin and S. A., Vadim, “New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine,” Molecules. vol. 28, no. 3651, 2023, doi: 10.3390/molecules28093651.
• D., Sohita, “Lazertinib: First Approval,” Drugs, vol. 81, pp. 1107–1113, 2021, doi: 10.1007/s40265-021-01533-x.
• H., Qi, J., Wen, and L., Li, “An Efficient Synthesis of Pemetrexed Disodium,” Jour. of Het. Chem., vol. 52, no. 5, pp. 15651569, 2015, doi: 10.1002/jhet.2164.
• S. F., Zakrzewski and A. M. Sansone, “Preparation of folinic acid (N5-formyltetrahydro folic acid),” Methods in Enzymology, vol. 18, part B, pp. 731733, 1971, doi: 10.1016/S0076-6879(71)18144-X.
• R., Roskoski Jr., “Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases,” Pharmacological Research, vol. 111, pp. 784803, 2016, doi: 10.1016/j.phrs.2016.07.038.
• X. J., Li, P., Nie, P., Herdewijn and J. G., Sun, “Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration,” Eur. J. Med. Chem, vol. 262, 115928, 2023, doi: 10.1016/j.ejmech.2023.115928.
• P., Shiri, S., Ramezanpour and A. M., Amani, “A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy,” Mol. Divers. vol. 26, pp. 2981–3002, 2022, doi: 10.1007/s11030-022-10406-8.